Novo Nordisk is trading at €37.02, down -3.20%, despite China approving Wegovy for MASH on September 10.
- The approval expands Wegovy’s potential market, but available reporting says shares briefly benefited before giving back gains in a weaker trading environment.
- Broader markets are rising on September 11, with no clear macro catalyst directly explaining the decline; profit-taking or company-specific sentiment unrelated to the approval is the most likely explanation.